Biophan completes phase II and III of Boston Scientific development agreement

Nov. 7, 2005 — Biophan Technologies Inc., a developer of next-generation medical technology, reported the completion of phase II and phase III of its development agreement with Boston Scientific. The satisfactory completion of these milestones allows the company to recognize $225,000 of previously received development payments as current quarter revenues.

Biophan said it expected to receive additional revenue from Boston Scientific in January 2006 as a result of the recently executed license agreement between the two companies.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.